Literature DB >> 25409287

Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial.

John C Fortney1, Jeffrey M Pyne1, Timothy A Kimbrell1, Teresa J Hudson1, Dean E Robinson2, Ronald Schneider3, William M Moore4, Paul J Custer5, Kathleen M Grubbs1, Paula P Schnurr6.   

Abstract

IMPORTANCE: Posttraumatic stress disorder (PTSD) is prevalent, persistent, and disabling. Although psychotherapy and pharmacotherapy have proven efficacious in randomized clinical trials, geographic barriers impede rural veterans from engaging in these evidence-based treatments.
OBJECTIVE: To test a telemedicine-based collaborative care model designed to improve engagement in evidence-based treatment of PTSD. DESIGN, SETTING, AND PARTICIPANTS: The Telemedicine Outreach for PTSD (TOP) study used a pragmatic randomized effectiveness trial design with intention-to-treat analyses. Outpatients were recruited from 11 Department of Veterans Affairs (VA) community-based outpatient clinics serving predominantly rural veterans. Inclusion required meeting diagnostic criteria for current PTSD according to the Clinician-Administered PTSD Scale. Exclusion criteria included receiving PTSD treatment at a VA medical center or a current diagnosis of schizophrenia, bipolar disorder, or substance dependence. Two hundred sixty-five veterans were enrolled from November 23, 2009, through September 28, 2011, randomized to usual care (UC) or the TOP intervention, and followed up for 12 months.
INTERVENTIONS: Off-site PTSD care teams located at VA medical centers supported on-site community-based outpatient clinic providers. Off-site PTSD care teams included telephone nurse care managers, telephone pharmacists, telepsychologists, and telepsychiatrists. Nurses conducted care management activities. Pharmacists reviewed medication histories. Psychologists delivered cognitive processing therapy via interactive video. Psychiatrists supervised the team and conducted interactive video psychiatric consultations. MAIN OUTCOMES AND MEASURES: The primary outcome was PTSD severity as measured by the Posttraumatic Diagnostic Scale. Process-of-care outcomes included medication prescribing and regimen adherence and initiation of and adherence to cognitive processing therapy.
RESULTS: During the 12-month follow-up period, 73 of the 133 patients randomized to TOP (54.9%) received cognitive processing therapy compared with 16 of 132 randomized to UC (12.1%) (odds ratio, 18.08 [95% CI, 7.96-41.06]; P < .001). Patients in the TOP arm had significantly larger decreases in Posttraumatic Diagnostic Scale scores (from 35.0 to 29.1) compared with those in the UC arm (from 33.5 to 32.1) at 6 months (β = -3.81; P = .002). Patients in the TOP arm also had significantly larger decreases in Posttraumatic Diagnostic Scale scores (from 35.0 to 30.1) compared with those in the UC arm (from 33.5 to 31.7) at 12 months (β = -2.49; P=.04). There were no significant group differences in the number of PTSD medications prescribed and adherence to medication regimens were not significant. Attendance at 8 or more sessions of cognitive processing therapy significantly predicted improvement in Posttraumatic Diagnostic Scale scores (β = -3.86 [95% CI, -7.19 to -0.54]; P = .02) and fully mediated the intervention effect at 12 months. CONCLUSIONS AND RELEVANCE: Telemedicine-based collaborative care can successfully engage rural veterans in evidence-based psychotherapy to improve PTSD outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00821678.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25409287     DOI: 10.1001/jamapsychiatry.2014.1575

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  62 in total

1.  Review of key telepsychiatry outcomes.

Authors:  Sam Hubley; Sarah B Lynch; Christopher Schneck; Marshall Thomas; Jay Shore
Journal:  World J Psychiatry       Date:  2016-06-22

2.  The clinical impact of pharmacist services on mental health collaborative teams: A systematic review.

Authors:  Brandy Davis; Jingjing Qian; Surachat Ngorsuraches; Ruth Jeminiwa; Kimberly B Garza
Journal:  J Am Pharm Assoc (2003)       Date:  2020-06-27

3.  Early Health System Experiences with Collaborative Care (CoCM) Billing Codes: a Qualitative Study of Leadership and Support Staff.

Authors:  Andrew D Carlo; Andrea Corage Baden; Rachelle L McCarty; Anna D H Ratzliff
Journal:  J Gen Intern Med       Date:  2019-07-31       Impact factor: 5.128

4.  Physical activity behavior change for older veterans after dysvascular amputation.

Authors:  Matthew J Miller; Jennifer Stevens-Lapsley; Thomas T Fields; David Coons; Susan Bray-Hall; William Sullivan; Cory L Christiansen
Journal:  Contemp Clin Trials       Date:  2017-01-31       Impact factor: 2.226

Review 5.  Remote Telepsychiatry Workforce: a Solution to Psychiatry's Workforce Issues.

Authors:  Jordan S Gardner; Brittany E Plaven; Peter Yellowlees; Jay H Shore
Journal:  Curr Psychiatry Rep       Date:  2020-01-27       Impact factor: 5.285

6.  Therapeutic alliance across trauma-focused and non-trauma-focused psychotherapies among veterans with PTSD.

Authors:  Jessica A Chen; John C Fortney; Hannah E Bergman; Kendall C Browne; Kathleen M Grubbs; Teresa J Hudson; Patrick J Raue
Journal:  Psychol Serv       Date:  2019-02-11

Review 7.  Best Practices in Tele-Teaming: Managing Virtual Teams in the Delivery of Care in Telepsychiatry.

Authors:  Jay H Shore
Journal:  Curr Psychiatry Rep       Date:  2019-07-08       Impact factor: 5.285

8.  PTSD Treatment for Veterans: What's Working, What's New, and What's Next.

Authors:  Miriam Reisman
Journal:  P T       Date:  2016-10

Review 9.  The Prevalence of Posttraumatic Stress Disorder in Primary Care: A Systematic Review.

Authors:  Margaret Spottswood; Dimitry S Davydow; Hsiang Huang
Journal:  Harv Rev Psychiatry       Date:  2017 Jul/Aug       Impact factor: 3.732

Review 10.  Telepsychiatry Today.

Authors:  Steven Chan; Michelle Parish; Peter Yellowlees
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.